-+ 0.00%
-+ 0.00%
-+ 0.00%
Repsol (BME:REP) Stock Catches Fire As Q3 Earnings Margin Jumps
Share
Listen to the news

Repsol carries a reputation as a value play in European energy, yet Q3 2026 results paint a sharper picture than that label suggests. The group delivered basic earnings per share of €2.56 on revenue of €20,036m, a hefty profit haul for a single quarter. Net income excluding extra items reached €2,805m, which puts a bright spotlight on profitability. The stock closed today at €30.73, with recent returns already positive over 7, 30 and 90 days. The price has been warming up to the story even before investors fully process how strong this latest quarter looks.

Impressed by how efficiently Repsol is turning revenue into profit but want a broader set of financially solid options in case this surge cools off? Check out our screener of stocks with strong balance sheets and fundamentals through the list of solid balance sheet and fundamentals stocks (202 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): €20,036m vs. €13,199m (very large year-on-year increase)
  • Net Income Excl. Extra Items (Q3 2026 vs. Q3 2025): €2,805m vs. €574m (very large year-on-year increase)
  • Basic EPS (Q3 2026 vs. Q3 2025): €2.56 vs. €0.49 (EPS more than 5x higher year-on-year)
  • Net Profit Margin (Trailing 12 Months vs. Prior Year): 9.3% vs. 2.1% (margin improved sharply over the past year)

Earnings tell part of the story, but investors who care about what they are paying for Repsol really focus on the cash being generated in the background. Looking at Repsol's cash flows alone, the stock could be a whopping 36% undervalued.

BME:REP Trailing 12-Month Earnings & Revenue History as at Oct 2026
BME:REP Trailing 12-Month Earnings & Revenue History as at Oct 2026

Repsol’s “Better Barrels, Lower Capex” Test In Q3

The bullish story argues that Repsol can turn project mix and tighter spending into sturdier cash generation rather than just bigger headline profit.

"The main thing that has to go right is that Repsol continues to translate its higher production levels, strong Iberian refining and trading premiums, and growing multi energy retail franchise into cash flow while keeping net capex within the €2.5 to €3.0b annual range and leverage low."

Q3 earnings of €2,805m excluding extra items against €20,036m of revenue leave a 14% quarterly profit margin, comfortably above the 9.3% trailing figure. That gap points to Repsol turning this operational mix into richer profitability, which supports the idea of higher quality cash flow even before drilling into capex and leverage data.

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there.

Repsol Bear Case: Fixed Capex, Policy Risk Still Loom Large

Bearish investors worry that Repsol has locked itself into a spend profile that could become painful if projects disappoint or policy turns harsher again.

"the concurrent commitment to keep annual Capex at about €2.5 to €3.0b through 2028 leaves limited flexibility if these barrels underperform expectations, which could strain free cash flow and earnings if commodity pricing weakens while spending remains high."

Q3 points in the opposite direction for now. Strong net income, low leverage and a fresh €950m buyback on top of higher 2026 dividends suggest current projects are generating enough surplus to fund that fixed program. The risk the quote flags is not visible in these results, it remains a forward sensitivity rather than a problem already emerging in the accounts.

Hunt Quiet Dislocations In Plain Sight

Repsol shows how sentiment can shift quickly once a strong quarter is reported. The real opportunity is carefully assessing stocks that could be undervalued before sentiment adjusts.

  • Company 1 - 25% below our estimate - uses reimbursement gains and patient care improvements to extend higher value prosthetics across clinic networks.
  • Company 2 - 16% below our estimate - turns added manufacturing capacity into packaging work for AI data center optics and broadening hyperscaler projects.
  • Company 3 - 36% below our estimate - shifts toward consumables and infection control equipment that connect hospitals to recurring equipment and service contracts.

Those are three of them. See all 201 potentially undervalued companies →

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending